Pharmacogenomic Insights from DNA You Already Have — from $49

Why Look for an Alternative?

Clinician-ordered pharmacogenomic panels are the gold standard for prescribing-critical decisions. But they come with barriers: a prescription requirement, out-of-pocket costs that can reach $330 or more without insurance, and 7–10 business days for results.

Meanwhile, over 40 million people already have raw DNA data from consumer testing services. That data contains the same pharmacogenomic variants — the key enzymes that affect how the body metabolizes medications. Raw data analysis unlocks those insights at a fraction of the cost.

How the Approaches Compare

Information as of March 2026. Verify current details directly with each provider.

What DecodeMyBio Reports Include

Upload your raw DNA file and receive a clinician-ready pharmacogenomic report covering:

• 13 pharmacogenes — including CYP2D6, CYP2C19, CYP2C9, VKORC1, SLCO1B1, and others central to drug metabolism
• 150+ drug-gene interactions — spanning multiple therapeutic areas including psychiatry, cardiology, pain management, and gastroenterology
• CPIC evidence levels — every interaction is graded Level A (strong evidence) or Level B (moderate evidence) based on peer-reviewed clinical guidelines
• Metabolizer phenotypes — your predicted metabolizer status (poor, intermediate, normal, rapid, ultrarapid) for each gene
• Clinician pocket summary — a one-page overview formatted for healthcare provider review
• Doctor-shareable PDF — download and share with your prescriber

Why Clinical Guidelines Matter

CPIC guidelines are developed by an international consortium of pharmacogenomics experts. Each guideline undergoes peer review and assigns evidence grades to specific drug-gene pairs:

• Level A: Strong evidence — genetic information should be used to change prescribing for this drug-gene pair.
• Level B: Moderate evidence — genetic information could be used to change prescribing.

DecodeMyBio reports include only drug-gene interactions with CPIC Level A or Level B evidence. This means every interaction in your report has been validated through clinical studies, meta-analyses, or replicated pharmacokinetic data. The guidelines are publicly available at cpicpgx.org.

Not all pharmacogenomic services use published guidelines. Some use proprietary scoring systems or combinatorial algorithms. While these may incorporate guideline data, their interpretation methodology is not publicly available for independent review.

Which Approach Is Right for You?

Choose a clinician-ordered panel if:

• Your doctor specifically recommends pharmacogenomic testing
• Your insurance covers the test — reducing or eliminating the $330+ cost
• You need maximum structural variant detection (gene deletions, duplications) for critical prescribing decisions
• You want results delivered directly to your prescribing clinician

Choose raw data analysis (DecodeMyBio) if:

• You already have DNA data from 23andMe, AncestryDNA, or a similar service
• You want results in minutes rather than 7–10 business days
• You want CPIC-guideline-backed analysis at $49, no prescription required
• You want to understand your pharmacogenomic profile before your next doctor's visit
• You want a multi-gene, multi-drug report covering 150+ interactions across therapeutic areas

Quick Decision Summary

• Have insurance + prescriber? → A clinician-ordered panel may be covered
• Already have 23andMe / AncestryDNA data? → DecodeMyBio ($49, instant results)
• Want published clinical guidelines, not a proprietary algorithm? → DecodeMyBio (CPIC + DPWG)

Frequently Asked Questions

Is raw data analysis as accurate as clinical pharmacogenomic testing?

Consumer genotyping arrays are highly accurate for the specific variants they test (typically >99% concordance). However, they test a predefined set of variants and cannot detect structural changes like gene deletions or duplications. Clinical-grade testing covers a broader range of variants. Consumer-grade analysis is informational and may be a useful starting point, but clinical testing may be recommended when critical prescribing decisions are involved.

Does insurance cover pharmacogenomic testing?

Clinician-ordered pharmacogenomic tests may be partially covered by insurance, depending on your plan and medical indication. Direct-to-consumer raw data analysis services are typically not covered by insurance but are generally lower in cost.

Can I show my report to my doctor?

Yes. DecodeMyBio reports include a clinician pocket summary designed for healthcare provider review. The report presents metabolizer phenotypes and drug-gene interactions with CPIC guideline references that clinicians can use in prescribing decisions.

What does metabolizer status mean?

Metabolizer status describes how quickly or slowly the body processes certain medications based on genetic variants. Categories include poor, intermediate, normal, rapid, and ultrarapid metabolizer. Each status has different clinical implications depending on the specific drug-gene pair. Read our plain-language guide to metabolizer status for a full explanation.

Do I need a prescription for pharmacogenomic analysis?

Clinician-ordered services require a prescription or clinician order. Raw data analysis services like DecodeMyBio do not require a prescription — you upload your existing DNA data directly. Regardless of the service used, pharmacogenomic results should be discussed with your healthcare provider before making any changes.

What is the best affordable alternative for pharmacogenomic testing?

If you already have DNA data from 23andMe or AncestryDNA, raw data analysis services can provide pharmacogenomic insights without a new test or prescription. DecodeMyBio maps results to published CPIC guidelines, covers 13 pharmacogenes and 150+ drug-gene interactions, and costs $49 as a one-time fee. For a detailed comparison of all options including specific providers and pricing breakdowns, see our full pharmacogenomic testing comparison.

What genes are analyzed?

DecodeMyBio analyzes 13 pharmacogenes from consumer DNA data using published CPIC and DPWG guidelines, including CYP2D6, CYP2C19, CYP2C9, VKORC1, SLCO1B1, and others. Clinical sequencing can detect a broader range of variants including structural changes, while consumer array analysis is limited to the variants present on the genotyping chip. See our methodology for details.

References

1. CPIC Guidelines — Clinical Pharmacogenetics Implementation Consortium. cpicpgx.org
2. PharmGKB — Pharmacogenomics Knowledgebase. pharmgkb.org
3. FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. fda.gov